8-K current report · filed Aug 7, 2026

ANI PHARMACEUTICALS INC (ANIP) 8-K Current Report: August 7, 2026

Item 2.02Item 7.01Item EX-99.2Item EX-99.1ANIP overview

Short answer

ANI PHARMACEUTICALS INC (ANIP) filed an 8-K current report with the SEC on August 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026 announced on August 7, 2026.

ANI PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026 announced on August 7, 2026
  • Press release Exhibit 99.1 contains the company’s reported financial results and management commentary

Item 7.01 · Regulation FD Disclosure

  • Updated investor presentation published August 7, 2026 under Regulation FD
  • Presentation may guide future investor and analyst meetings
  • Exhibit 99.2 contains substantive company information for investor review

Item EX-99.1 · Exhibit EX-99.1

  • Q2 net revenue $266.0M, up 25.9%, with adjusted EBITDA $71.6M, up 32.4%, signaling strong operating leverage
  • Cortrophin Gel revenue $117.1M, up 43.5%, driven by core specialties and newly operational gout-focused sales coverage
  • Gout expansion targets approximately 285,000 patients, with over 95% of representatives generating multiple new cases
  • 2026 total revenue guidance reaffirmed at $1,080-$1,140M and adjusted EBITDA at $285-$300M
  • Cortrophin guidance reduced to $520-$540M from $540-$575M, while a $100M share repurchase program supports capital returns through May 2029

Item EX-99.2 · Exhibit EX-99.2

  • 2026 guidance reaffirmed: revenue $1,080-$1,140M, adjusted EBITDA $285-$300M, adjusted EPS $9.19-$9.69
  • Cortrophin Gel revenue forecast $520-$540M, up 50%-55%, making commercialization execution the primary growth driver
  • Rare Disease expected to approach 60% of 2026 revenue, accelerating ANI’s strategic shift beyond generics
  • Gout expansion increased sales force approximately 50%, from ~120 to ~180 representatives, targeting ~285,000 addressable patients
  • Generics pipeline targets at least 15 launches annually, supporting cash generation and funding Rare Disease investment

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ANI PHARMACEUTICALS INC 8-K filings

Get the next ANIP 8-K as it lands

Follow ANIP for push alerts, or ask the research agent what this filing means.